News

Mission

The Impact Journals news page hosts articles about important news stories from our journals and within the scientific community. Visit this page for the latest in medical advances, pharmaceutical progress, conference reports, and more.

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer

Oncotarget

March 27, 2024

PRESS RELEASE: On March 19, 2024, a new research paper was published in Oncotarget, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.” continue reading »

Chlorogenic Acid Prevents Ovariectomized-induced Bone Loss

News

March 26, 2024

PRESS RELEASE: A new research paper was published in Aging’s Volume 16, Issue 5, entitled, “Chlorogenic acid prevents ovariectomized-induced bone loss by facilitating osteoblast functions and suppressing osteoclast formation.” continue reading »

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

News

March 25, 2024

PRESS RELEASE: On March 14, 2024, a new research paper was published in Oncotarget, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.” continue reading »

FoxO6-mediated ApoC3 Upregulation Promotes Hepatic Steatosis and Hyperlipidemia in HFD Aged Rats

Aging

March 20, 2024

PRESS RELEASE: On March 3, 2024, a new research paper was published in Aging's Volume 16, Issue 5, entitled, “FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet.” continue reading »

Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal®

News

March 20, 2024

PRESS RELEASE: On March 14, 2024, a new research paper was published in Oncotarget, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.” continue reading »

« Previous 1 … 31 32 33 34 35 … 105 Next »